







TOGAS 2024

September 12, 2024

Towards gastric cancer screening implementation in the European Union

CONFERENCE PROGRAMME

Fundação Eng. António de Almeida Rua Tenente Valadim, 231/325 | Porto, Portugal



Dear colleagues, Dear participants,

We are delighted to welcome you to the second TOGAS conference in Porto, aimed to exchange view-points on gastric cancer screening implementation in Europe.

Gastric cancer remains a tough challenge, claiming lives and inflicting immeasurable suffering on individuals and families worldwide.

We anticipate that the meeting will deliver the best global experience in the field, while collecting important feedback from Member State representatives on their willingness and readiness to implement gastric cancer prevention within their healthcare priorities. Therefore, your participation and active feedback is of critical importance.

The TOGAS project is expected to develop a guide for implementation of gastric cancer prevention in Europe. This includes running pilot studies, collecting feedback from the target groups and decision-makers, as well as analysing cost-effectiveness of gastric cancer prevention under various conditions.

Recent recommendations by the Council of the European Union have suggested that gastric cancer screening programs should be considered in countries or regions within countries with high gastric cancer incidence and death rates. Of note, in countries with low gastric cancer incidence, this is still a critical issue in particular population groups, including in immigrants.

We anticipate that the conference will unveil answers to the potential questions, decrease the potential level of uncertainty, and facilitate gastric cancer prevention across Europe. To achieve this, your participation is essential!

In the pages that follow, we will map a course towards a future where gastric cancer is not only treatable but preventable. Each contribution, each insight, and each decision made in the course of this project brings us one step closer to that vision.

Let us rise to the challenge before us and begin this meeting with a shared sense of purpose and determination, knowing that our collective efforts can save lives!



Mārcis Leja, Riga, Latvia Scientific Manager



08.00 - 08.10 WELCOMING

José Carlos Machado, Porto, Portugal & Mārcis Leja, Riga, Latvia

08.10 - 09.50 SESSION 1 - STATE OF THE PLAY

Chair: Constanza Camargo, Rockville, MD, USA

08.10 - 08.25

01.01. The burden of gastric cancer – globally and in Europe Jin Young Park, Lyon, France

08.25 - 08.40

01.02. General principles of population-based screening Arunah Chandran (IARC), Lyon, France

08.40 - 08.55

01.03. General overview of gastric cancer screening and prevention Jyh-Ming Liou, Taipei, Taiwan

08.55 - 09.10

01.04. *Helicobacter pylori* infection – the benefits and risks of population-based eradication

Jan Bornschein, Oxford, United Kingdom | Riga, Latvia

09.10 - 09.25

01.05 What are the differences (*H.pylori* and gastric cancer) between the East and the West

Yoshio Yamaoka, Yufu, Japan

09.25 - 09.40

01.06. Is gastric cancer prevention cost-effective? Iris Lansdorp – Vogelaar, Rotterdam, The Netherlands

09.40 - 09.50

Panel Discussion

09.50 - 10.20

Coffee Break



10.20 - 11.45 SESSION 2 - GLOBAL EXPERIENCE

Chair: Markus Gerhard, Munich, Germany

10.20 - 10.35

02.01. Gastric cancer screening and prevention in Japan Hidekazu Suzuki, Tokyo, Japan

10.35 - 10.50

02.02. Gastric cancer screening and prevention in South Korea Hwoon-Yong Jung, Seoul, South Korea

10.50 - 11.05

02.03 Linqu county study status Wen Qing Li, Beijing, China

11.05 - 11.20

02.04. What is ongoing in Latin America? Arnoldo Riquelme, Santiago, Chile

11.20 - 11.35

02.05 Overview of the Think Tank on Advancing Gastric Cancer Prevention results (US)

Constanza Camargo, Rockville, MD, USA

11.35 - 11.45

Panel discussion

11.45 - 12.45

Lunch Break

PROGRAMME



^{*} This project has received funding from the European Union programme EU4Health under Grant Agreement No 101101252.

^{*} Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.

12.45 - 14.10 SESSION 3 - THE PROGRESS OF GASTRIC CANCER PREVENTION IN EUROPE

Chair: Jochen Weight, Magdeburg, Germany

12.45 - 13.00

03.01. Screening recommendations of the European Commission (Beating Cancer Plan, SAPEA report, EC Recommendation)
Mārcis Leja, Riga, Latvia

13.00 - 13.15

03.02. Experience from the population-based projects in Slovenia and other countries

Bojan Tepeš, Ljubljana, Slovenia

13.15 - 13.30

03.03. Other ongoing gastric prevention activities in Europe (GISTAR, TOGAS, EUCanScreen)

Danute Ražuka-Ebela, Riga, Latvia

13.30 - 13.45

03.04. The achievements of PRAISE-U consortium to facilitate prostate cancer screening in Europe

Hendrik Van Poppel, Leuven, Belgium

13.45 - 14.00

03.05. The achievements of SOLACE consortium to facilitate lung cancer screening in Europe

Torsten Blum, Berlin, Germany

14.00-14.10

Panel Discussion



14.10 - 15.10 SESSION 4 - STAKEHOLDERS FEEDBACK

Chair: Colm O'Morain, Dublin, Ireland

14.10 - 14.25

04.01. Ongoing survey of the Member State authorities Thomas More Janet Takens, Brussels, Belgium

14.25 - 14.40

04.02. Feedback from the screening target population Zorana Maravic | DiCE, Belgrade, Serbia (*TBC*)

14.40 - 14.55

Feeback from the medical professionals Līga Krauze, Riga, Latvia

14.55 - 15.10

Panel Discussion

15.10 - 15.40

Coffee Break

15.40 - 16.55 SESSION 5 - LARGE SCALE DATA TO SUPPORT GASTRIC CANCER PREVENTION

Chair: Iris Lansdorp - Vogelaar, Rotterdam, The Netherlands

15.40 - 15.55

05.01. Personalized data in cancer screening Aapeli Nevala, Helsinki, Finland

15.55 - 16.10

05.02. What is ECIS?
Raguel Carvalho, Varese, Italy

PROGRAMME



15.40 - 16.55 SESSION 5 - LARGE SCALE DATA TO SUPPORT GASTRIC CANCER PREVENTION

cont.

16.10 - 16.25

05.03. Potential indicator development for gastric cancer screening – experience from adapting CanScreen-ECIS indicators for prostate cancer screening Arunah Chandran

16.25 - 16.35

05.04. Data harmonozation: TOGAS. CARECOL, EUCanScreen Inese Poļaka, Riga, Latvia

16.35 - 16.45

05.05. How Al could help: AIDA efforts
Tania Fleitas Kanonnikoff, Valencia, Spain

16.45 - 16.55

Panel Discussion

16.55 - 17.30 SESSION 6 - ROUND TABLE ON COUNTRY RELATED ISSUES, FEEDBACK, DISCUSSION

Chair: Mārcis Leja, Riga, Latvia

16.55 - 17.25

Country representatives

17.25 - 17.30

Final remarks

Mārcis Leja, Riga, Latvia



NOTES

- LATVIJAS UNIVERSITATE
- NACIONALNI INSTITUT ZA JAVNO ZDRAVJE
- CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
- ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM
- DIGESTIVE CANCERS EUROPE DICE
- INSTITUTO PORTUGUES DE ONCOLOGIA DO PORTO FRANCISCO GENTIL, EPE
- SERVICIO MADRILENO DE SALUD
- FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO LA PRINCESA
- LIETUVOS SVEIKATOS MOKSLU UNIVERSITETAS
- UNIVERSITATEA DE MEDICINA SI FARMACIE IULIU HATIEGANU CLUJ-NAPOCA
- EUROPEAN HELICOBACTER & MICROBIOTA STUDY GROUP
- EUROPEAN CANCER ORGANISATION
- UNIWERSYTET MEDYCZNY IM PIASTOW SLASKICH WE WROCLAWIU
- KLINICKI BOLNICKI CENTAR ZAGREB
- KLINICKI BOLNICKI CENTAR RIJEKA
- THOMAS MORE MECHELEN-ANTWERPEN
- BEACON HOSPITAL SANDYFORD LIMITED
- OTTO-VON-GUERICKE-UNIVERSITAET MAGDEBURG
- NARODOWY INSTYTUT ONKOLOGII IM. MARII SKLODOWSKIEJ-CURIE -PANSTWOWY INSTYTUT BADAWCZY
- CENTRE INTERNATIONAL DE RECHERCHE SUR LE CANCER
- EUROPAISCHE VEREINIGUNG DER GASTROINTESTINALEN ONKOLOGIE (EUROPEAN SOCIETY OF DIGESTIVE ONCOLOGY - ESDO)





